Download the ebooks for this Research Topic:
Volume I.A: ¦PDF¦ ¦EPUB
Volume I.B: ¦PDF¦ ¦EPUB

Hepatic-biliary-pancreatic cancers, mainly including hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, are highly aggressive malignancies with few treatment options and poor prognoses. Effects of the traditional systemic treatments such as chemotherapy and radiotherapy, are quite limited to hepatic-biliary-pancreatic cancers. For the patients who suffer from hepatic-biliary-pancreatic cancer and lose the opportunity of radical surgery, few targeted drugs are available. Even for the drugs in clinical trial, potential drug targets and prognostic biomarkers for hepatic-biliary-pancreatic cancer are less studied compared to other common cancers such as lung cancer. Prognostic biomarker study is the initiation to explore new drug targets and revelation of the underlying mechanisms of tumor progression.

Immunotherapy, especially PD1 or PD-L1 antagonists, has exhibited potent treatment effects on cancers. To date, many PD1 drugs are available for cancer treatment, and more than one hundred PD1 drugs are in clinical trial. However, how to screen out the sensitive patients and predict the efficacy of immunotherapy are still unsolved problems. Moreover, the predictive biomarkers and treatment guidelines of immunotherapy for hepatobiliary tumors are barely investigated.

In this Research Topic, we focus on the biomarkers for immunotherapy of hepatic-biliary-pancreatic tumors, and the discovery of more predictive or prognostic biomarkers, which stratify appropriate patients for immunotherapy, and indicate prognosis or immunotherapeutic effects for the patients with hepatic-biliary-pancreatic tumors.

We welcome submissions of Review, Mini-Review, Clinical Trial and Original Research articles covering, but not limited to, the following topics:
1. new biomarkers predicting the effects of the targeted therapy or immunotherapy of hepatic-biliary-pancreatic cancers.
2. new drug targets of the targeted therapy or immunotherapy of hepatic-biliary-pancreatic cancers.
3. new clinical trials or studies in the targeted therapy or immunotherapy of hepatic-biliary-pancreatic cancers.
4. new targeted drugs or immunotherapeutic drugs of hepatic-biliary-pancreatic cancers.

Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

Submit your idea

Impact

Frontiers in Oncology

Participating Journals

Impact